In tumour progression, several studies have demonstrated the impact of the insulin/IGF system on cancer cell behaviour, particularly on the acquisition of the malignant phenotype by regulating the epithelial-mesenchymal transition (EMT) program [2,3,4,5]. This evidence concerns the gene IGF1 and neoplasm.